Reticular
Houston, USA· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-proteomics platform for discovering novel drug targets and biomarkers.
OncologyNeuroscience
Technology Platform
An integrated platform combining high-throughput proteomics with AI to model disease networks and identify novel therapeutic targets.
Opportunities
The ability to deconvolute complex diseases like cancer and neurodegeneration presents a vast opportunity for first-in-class drugs.
Risk Factors
High technical risk that their novel target discoveries may not be 'druggable' or may have undiscovered biological liabilities.
Competitive Landscape
A first-mover in AI-driven proteomics, but faces competition from companies scaling single-cell and spatial proteomics.